Phase III RCT in Chinese patients with moderate-to-severe plaque psoriasis: at week 16, picankibart 200 mg vs placebo achieved PASI 90 in 80.3% vs 2.0% and sPGA 0/1 in 93.5% vs 13.1%; response was maintained to week 52.
RCT
Gao et al. A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis